TL;DR: Hyperbaric oxygen therapy (HBOT) is not a Health Canada-approved indication for hair growth, hair loss, or alopecia of any cause. Evidence tier: D (preliminary mechanistic data plus small post-transplant trials; no randomised controlled trial evidence for cosmetic hair regrowth in healthy adults or for autoimmune alopecia). A 2026 observational study found measurable changes in hair-follicle characteristics in healthy subjects after HBOT, and small clinical trials have explored HBOT as an adjunct to hair-transplant surgery, but no large randomised trial has demonstrated that HBOT regrows hair on a balding scalp. Canadians considering self-pay HBOT for hair growth should treat current data as preliminary and weigh the cost against the lack of definitive evidence.

Search interest in “hyperbaric oxygen therapy hair growth” has grown in recent years, driven partly by social-media discussion, partly by the broader cosmetic-medicine market, and partly by genuine clinical curiosity about whether oxygen delivery to hair follicles could influence regrowth. This review summarises what the 2020 to 2026 peer-reviewed literature actually says, distinguishes three very different clinical contexts that often get conflated, and outlines what Canadian patients should know before pursuing private HBOT for hair-related goals.

Canada Hyperbarics maintains an independent index of more than 14,000 peer-reviewed HBOT studies. Patients can browse the broader research database on the research page, and the directory of hospitals and verified private facilities shows which clinics across Canada operate clinical-grade hyperbaric chambers.

Three different “HBOT and hair” questions, often conflated

Before reviewing the evidence, it is important to separate three distinct clinical scenarios that are commonly grouped under “HBOT for hair growth”:

  • Cosmetic hair regrowth in healthy adults with male-pattern or female-pattern hair thinning. This is the dominant search intent and the area with the weakest evidence.
  • HBOT as an adjunct to hair-transplantation surgery, aimed at improving graft survival by reducing ischaemic damage in the immediate postoperative period. This is the area with the most clinical-trial activity.
  • Autoimmune alopecia (alopecia areata, totalis, universalis) and other medical hair-loss conditions. This is the area where mechanistic rationale exists but human trial data is essentially absent.

What the 2020 to 2026 evidence actually shows

1. Cosmetic hair regrowth in healthy adults: preliminary mechanistic data only

The single most relevant 2026 publication is Lee et al., “Preliminary Effects of Hyperbaric Oxygen Therapy on Hair Follicle Characteristics in Healthy Subjects” (PMID 41749779, Bioengineering, 2026). This study used objective trichoscopic measurements of follicle density, hairs per follicle, follicle volume, and shaft thickness in healthy participants after a course of HBOT. The authors reported measurable changes in some follicle parameters, and framed the findings explicitly as preliminary, supporting the case for larger controlled studies rather than as evidence that HBOT regrows hair on a balding scalp.

Critically, this study did not enrol participants with diagnosed androgenetic alopecia (the most common form of patterned hair loss), and it did not compare HBOT against a sham-control condition. As of May 2026, no published randomised controlled trial has tested HBOT as a primary treatment for androgenetic alopecia, female-pattern hair loss, or telogen effluvium in humans. The evidence base for cosmetic hair-regrowth claims is therefore best described as preliminary and hypothesis-generating.

2. HBOT after hair transplantation: small clinical trials with cautiously positive signals

This is the most active research area within the broader “HBOT and hair” question. Two clinical reports stand out:

  • Fan et al., “The effect of hyperbaric oxygen therapy combined with hair transplantation surgery for the treatment of alopecia” (PMID 32770782, J Cosmet Dermatol, 2021) reported that adjunctive HBOT was associated with reduced ischaemia-reperfusion injury and enhanced capillary regeneration around transplanted follicles, with the authors describing improved graft survival in treated patients.
  • Giardiello et al., “Hyperbaric Oxygen Therapy for Enhanced Postoperative Recovery in Hair Transplantation” (PMID 41556017, Cureus, 2025) evaluated HBOT in the immediate postoperative period after transplant procedures and reported reduced healing delays and improved early outcomes in treated patients.

These trials are small, single-centre, and largely uncontrolled or weakly controlled. The mechanistic rationale (HBOT improves tissue oxygenation in the freshly transplanted graft bed during the critical 24 to 72 hour window when capillary in-growth determines graft survival) is biologically plausible and well-aligned with HBOT’s established role in compromised skin grafts and flaps, which is one of the 14 Health Canada-recognised conditions. However, this is a question for the hair-transplant surgeon, not a free-standing cosmetic HBOT decision, and any post-transplant HBOT decision is best made jointly with the operating surgeon.

3. Autoimmune alopecia: mechanistic interest, no human trial data

Alopecia areata, totalis, and universalis are autoimmune conditions in which T-cells attack the hair follicle. The mechanistic case for HBOT in these conditions rests on HBOT’s known effects on inflammation and immune modulation in other indications. However, as of May 2026, no published clinical trial has tested HBOT as a treatment for any form of autoimmune alopecia. Patient testimonials exist online but are not peer-reviewed evidence and should be treated as anecdotal.

The mechanistic rationale (and where it stops)

Hair follicles are metabolically active mini-organs that cycle between active growth (anagen), regression (catagen), and rest (telogen). Adequate scalp blood flow and oxygen delivery to the dermal papilla are required for sustained anagen. Experimental work in animal models supports the basic biology: Kato and colleagues, “The Effects of Ischemia and Hyperoxygenation on Hair Growth and Cycle” (PMID 32727280, Organogenesis, 2020), showed that experimentally induced skin ischaemia in mice reduced hair growth rate, shaft size, and pigmentation during anagen, while hyperoxygenation conditions tended in the opposite direction.

The leap from mouse-model data to clinical cosmetic claims is substantial. Mouse hair cycles differ from human hair cycles in important ways, and the mechanistic plausibility that ischaemia is harmful to follicles does not by itself establish that adding oxygen at hyperbaric pressures produces measurable cosmetic regrowth in adults with patterned hair loss. The conservative interpretation is that the underlying biology is interesting and worth studying further, while the human evidence to support cosmetic regrowth claims is not yet available.

What about clinics offering HBOT for hair growth?

Some private wellness clinics in Canada and internationally include hair growth or scalp health in their HBOT marketing material. Health Canada’s regulatory framework lists 14 conditions for which HBOT is the established treatment; hair growth, alopecia, and scalp conditions are not among them (see the recognised conditions list). Marketing claims that present HBOT as a proven hair-growth treatment go beyond what the current peer-reviewed evidence supports and should be evaluated with the same critical eye applied to any cosmetic-medicine claim.

Cost is a meaningful consideration. Private-pay HBOT in Canada typically costs $175 to $350 per session, and meaningful course lengths for any HBOT indication run 20 to 40 sessions or more (see our national cost guide). A 30-session course at the typical mid-range rate is approximately $7,500 to $9,000 out of pocket. For a treatment with no Phase II or Phase III evidence in the specific application, that financial commitment deserves careful thought.

Is HBOT for hair growth covered in Canada?

No. None of the provincial health plans (OHIP in Ontario, MSP in BC, RAMQ in Quebec, AHCIP in Alberta, MSI in Nova Scotia, Manitoba Health, Saskatchewan Health, Medicare NB, PEI Health, or MCP in Newfoundland and Labrador) cover HBOT for hair growth, alopecia, or any cosmetic hair-related indication. Hospital-based hyperbaric programmes accept referrals only for the 14 Health Canada-recognised conditions, all of which require a clinical (not cosmetic) indication and a physician referral.

HBOT delivered alongside or after hair-transplantation surgery, if it happens, is a private-pay arrangement coordinated with the transplant surgeon and is not separately publicly funded. Some extended health plans cover HBOT for specific medical indications but not for cosmetic ones; if you carry private coverage and are considering HBOT for any reason, confirm with your insurer before booking.

Bottom line for Canadians considering HBOT for hair growth

  • The evidence does not currently support cosmetic hair regrowth as an HBOT indication. One 2026 preliminary observational study examined follicle measurements in healthy subjects; no randomised controlled trial has tested HBOT for androgenetic or pattern hair loss.
  • There is a small but cautiously positive evidence base for HBOT as an adjunct to hair-transplantation surgery, focused on graft survival. This is a question for the operating surgeon, not a standalone cosmetic decision.
  • There is no human clinical-trial evidence for HBOT in autoimmune alopecia (alopecia areata, totalis, universalis). Patient testimonials are not equivalent to peer-reviewed evidence.
  • No provincial health plan covers HBOT for hair growth. A course is entirely out of pocket and typically totals $7,500 to $14,000 at private clinics.
  • If you proceed, do it with eyes open. Speak with your physician, ask the clinic for specific evidence-based references for the hair-growth claim, and budget realistically.

Frequently asked questions

Does hyperbaric oxygen therapy actually regrow hair?

The published evidence does not support that claim in healthy adults with patterned hair loss. One 2026 preliminary observational study (Lee et al., PMID 41749779) measured changes in hair-follicle characteristics in healthy subjects after HBOT, but did not compare HBOT against a sham-control condition and did not enrol participants with diagnosed androgenetic alopecia. No published randomised controlled trial has tested HBOT for hair regrowth in pattern hair loss.

Is HBOT covered by OHIP, MSP, RAMQ, or any provincial plan for hair growth?

No. Provincial health plans cover HBOT only for the 14 Health Canada-recognised conditions, all of which are clinical (not cosmetic) indications and require a physician referral. Hair growth, alopecia, and scalp-related cosmetic indications are not on that list.

How much does HBOT for hair growth cost out of pocket in Canada?

Private-pay HBOT in Canada typically costs $175 to $350 per session, and any meaningful course length runs 20 to 40 sessions. A 30-session course at the typical mid-range rate is approximately $7,500 to $9,000 out of pocket; a 40-session course can reach $12,000 to $14,000. For a treatment without Phase II or Phase III evidence in this indication, this is a substantial financial commitment.

Does HBOT help after a hair transplant?

Small clinical reports (Fan 2021, Giardiello 2025) suggest HBOT in the immediate postoperative period may reduce ischaemia-reperfusion injury and improve early graft healing. The mechanistic case is plausible and aligned with HBOT’s established role in compromised skin grafts and flaps. However, the evidence base is limited, and any post-transplant HBOT decision should be made jointly with the transplant surgeon, not pursued independently.

What about alopecia areata or autoimmune hair loss?

As of May 2026, no published clinical trial has tested HBOT for any form of autoimmune alopecia (alopecia areata, totalis, or universalis). Patient testimonials exist online but are not peer-reviewed evidence. If you have autoimmune hair loss, the standard of care is established and is best managed by a dermatologist; HBOT is not a recognised treatment in this category.

Why is the evidence so limited?

Hair-growth claims for HBOT are a recent area of interest, and randomised controlled trials in cosmetic indications are expensive to run, hard to blind (chambers are visually distinctive), and have less obvious sources of public or industry funding than trials in conditions already recognised for HBOT (radiation injury, diabetic foot ulcers, decompression sickness). Until larger, properly controlled studies are funded and published, the evidence base for cosmetic hair-regrowth claims will remain thin.

What should I ask a clinic that offers HBOT for hair growth?

Ask for the specific peer-reviewed clinical-trial citations supporting the hair-growth claim, the proposed protocol (pressure in ATA, session length in minutes, total course length), the all-in out-of-pocket cost, the clinic’s policy on patients who do not see improvement, and whether the chamber is a Health Canada-licensed clinical-grade chamber. Compare the answers against the published evidence base before committing.

This review is for informational purposes only and is not medical advice. Consult a physician or dermatologist before pursuing any treatment for hair loss. Canada Hyperbarics is an independent information resource and is not affiliated with any private clinic offering HBOT.